An in-vitro model for tumor immunotherapy with antibody heteroconjugates.
about
Cell retargeting by bispecific monoclonal antibodies. Evidence of bypass of intratumor susceptibility to cell lysis in human melanoma.Monoclonal antibody-targeted superantigens: a different class of anti-tumor agents.Gene transfer by retrovirus-derived shuttle vectors in the generation of murine bispecific monoclonal antibodies.Characterization of a bispecific FLT3 X CD3 antibody in an improved, recombinant format for the treatment of leukemia.Targeting of drugs to cell surface receptors.Mono- and bivalent antibody fragments produced in Escherichia coli: engineering, folding and antigen binding.
P2860
An in-vitro model for tumor immunotherapy with antibody heteroconjugates.
description
1988 nî lūn-bûn
@nan
1988年の論文
@ja
1988年学术文章
@wuu
1988年学术文章
@zh-cn
1988年学术文章
@zh-hans
1988年学术文章
@zh-my
1988年学术文章
@zh-sg
1988年學術文章
@yue
1988年學術文章
@zh
1988年學術文章
@zh-hant
name
An in-vitro model for tumor immunotherapy with antibody heteroconjugates.
@en
An in-vitro model for tumor immunotherapy with antibody heteroconjugates.
@nl
type
label
An in-vitro model for tumor immunotherapy with antibody heteroconjugates.
@en
An in-vitro model for tumor immunotherapy with antibody heteroconjugates.
@nl
prefLabel
An in-vitro model for tumor immunotherapy with antibody heteroconjugates.
@en
An in-vitro model for tumor immunotherapy with antibody heteroconjugates.
@nl
P1433
P1476
An in-vitro model for tumor immunotherapy with antibody heteroconjugates.
@en
P2093
P304
P356
10.1016/0167-5699(88)91304-7
P577
1988-09-01T00:00:00Z